Leading the development of new next-generation biopharmaceutical products.
The treatment of breast cancer has evolved over time. Monoclonal antibody-based therapies that target specific proteins, or markers, on the surface of breast cancer cells have revolutionized treatment. Anti-HER2 monoclonal antibody is one such treatment that targets the human epidermal growth factor receptor 2 marker (HER2) present on approximately 25% of breast cancers. However, over time a significant fraction of women can become resistant to these treatments.
GeneOne is applying a combination approach to develop a nucleic acid-based, dual-specific molecule designed for the treatment of HER2-resistant breast cancers.
GLS-5100 Prevention of herpes zoster (shingles)
GLS-5140 Prevention of severe fever with thrombocytopenia syndrome (SFTS)
Prevention of Middle East respiratory syndrome coronavirus (MERS-CoV) infection
GLS-5700 Prevention of Zika virus infection
GLS-6100/GLS-6150 Prevention of hepatitis C
GLS-3000(mRNA) Prevention of COVID-19 disease
GLS-5310(DNA) Prevention of COVID-19 disease
GLS-5310(DNA) Prevention of coronavirus disease 2019 (COVID-19)
GLS-7000 HER2-targeted mAb Drug Resistant Breast Cancer
GLS-7100 Hemophilia A
GLS-8000 Prevention of Chronic Hepatitis B/Hepatitis B
GLS-8100 Rheumatoid Arthritis
GLS-1027 Acute ischemic nephritis
GLS-1027 COVID-19 Pneumonitis
GLS-1200 Chronic Rhinosinusitis
GLS-1200 COVID-19 Prophylaxis
GLS-1200 Influenza and Common cold viruses